Abstract
A series of 2,4,5-trisubstituted pyrimidines have been synthesised and characterised, which exhibited potent CDK inhibition and anti-proliferative activities. The structure-activity relationship is analysed and a rational for CDK9 selectivity is discussed. Compound 9s, possessing appreciable selectivity for CDK9 over other CDKs, is capable of activating caspase 3, reducing the level of Mcl-1 anti-apoptotic protein, and inducing cancer cell apoptosis.
Keywords:
Anti-cancer drug discovery; CDK9 inhibitors; Inhibitor design; Mcl-1 anti-apoptotic proteins; RNA polymerase II.
Crown Copyright © 2013. Published by Elsevier Masson SAS. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Proliferation / drug effects
-
Cyclin-Dependent Kinases / antagonists & inhibitors*
-
Cyclin-Dependent Kinases / metabolism
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
HCT116 Cells
-
Humans
-
MCF-7 Cells
-
Models, Molecular
-
Molecular Structure
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Cyclin-Dependent Kinases
-
pyrimidine